S.boulardii CNCMI-3799: The clinical study – children’s gut health

Acute diarrhea and children

Saccharomyces boulardii CNCMI-3799 is a yeast probiotic that can support pediatric digestive health, particularly in acute gastroenteritis and acute diarrhea, where clinical evidence shows it can reduce diarrhea duration and severity.

According to the World Health Organization, diarrheal diseases are the second leading cause of death in children under the age of five. In young children, acute gastroenteritis and diarrhea can quickly lead to fluid and electrolyte losses; if these losses are not replenished, dehydration occurs. Diarrhea is also a significant cause of malnourishment, increasing vulnerability to future diarrhea episodes and other illnesses. For brands developing research-backed children’s gut health solutions, this makes strain-specific probiotic evidence especially relevant.
Lynside® Pro S. boulardii CNCM I-3799 has demonstrated beneficial effects for managing diarrhea in children. This yeast probiotic supports healthy gut microbiota composition and helps manage digestive symptoms in pediatric patients.

Saccharomyces boulardii is a probiotic yeast that provides numerous benefits to improve digestive health. It may also help limit bad bacteria and block certain harmful bacterial toxins. It works by restoring and balancing gut bacteria, helping to alleviate diarrhea caused by factors such as antibiotics, infections and stress. Notably, Saccharomyces boulardii has been shown to significantly reduce the risk of antibiotic-associated diarrhea by 80%. It has also been shown to reduce diarrhea duration by 1.63 days and improve symptoms when used for treating acute diarrhea.

A published clinical trial in pediatric patients included 100 infants and children younger than 36 months to evaluate the safety and efficacy of the probiotic yeast strain Lynside® Pro SCB S. boulardii CNCM I-3799 in the treatment of acute diarrhea. The study design compared results of S. boulardii administration to control.

The results confirm that S. boulardii CNCM I-3799 supplementation is consistent with the scientific literature demonstrating the benefits of Saccharomyces boulardii for digestive health. These findings align with evidence from randomized controlled trials, clinical trials, systematic review, and meta analysis on treating acute diarrhea in children. Across trials, treatment with the probiotic yeast strain was well tolerated: no adverse reactions were reported in the pediatric patients.

NOTE: Probiotic supplementation does not replace dehydration management in children with diarrhea, and a pediatrician or other healthcare professional should always be consulted before use. S. boulardii should not be used in children with weakened immune systems, in premature infants or infants under 1 kg, in critically ill or severely malnourished children, or in children with central venous catheters. It should also not be given with antifungal medications, and it should not be mixed into hot foods or drinks because heat can reduce yeast viability.